BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a sell rating to a hold rating in a research report released on Friday.
A number of other equities research analysts have also recently commented on the company. SunTrust Banks reiterated a buy rating and set a $3.25 target price on shares of BioScrip in a report on Thursday, March 8th. Craig Hallum reiterated a buy rating and set a $3.50 target price on shares of BioScrip in a report on Thursday, March 8th. Finally, Zacks Investment Research cut BioScrip from a hold rating to a sell rating in a report on Tuesday, March 13th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $3.45.
NASDAQ BIOS opened at $2.43 on Friday. BioScrip has a 1-year low of $1.80 and a 1-year high of $3.39. The company has a market capitalization of $333.95 million, a P/E ratio of -5.52 and a beta of 0.08. The company has a quick ratio of 1.30, a current ratio of 1.70 and a debt-to-equity ratio of -4.79.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, May 10th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The business had revenue of $168.60 million during the quarter, compared to analysts’ expectations of $164.72 million. The business’s revenue was down 22.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.18) EPS. equities research analysts expect that BioScrip will post -0.31 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in BioScrip by 40.9% during the 3rd quarter. Wells Fargo & Company MN now owns 161,814 shares of the company’s stock valued at $445,000 after buying an additional 47,004 shares during the last quarter. Gabelli Funds LLC grew its holdings in BioScrip by 2.0% during the 4th quarter. Gabelli Funds LLC now owns 10,357,832 shares of the company’s stock valued at $30,141,000 after buying an additional 205,379 shares during the last quarter. Royce & Associates LP grew its holdings in BioScrip by 942.6% during the 4th quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after buying an additional 1,649,500 shares during the last quarter. Gotham Asset Management LLC acquired a new stake in BioScrip during the 4th quarter valued at $114,000. Finally, Two Sigma Advisers LP grew its holdings in BioScrip by 100.4% during the 4th quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after buying an additional 64,238 shares during the last quarter. Hedge funds and other institutional investors own 85.46% of the company’s stock.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.